Human papillomavirus vaccine trials and tribulations

As of December 2014, there were 3 approved vaccines for human papillomavirus (HPV): bivalent Cervarix (GlaxoSmithKline, New York, NY), quadrivalent Gardasil (Merck and Co, Kenilworth, NJ), and 9-valent Gardasil-9 (Merck and Co). The average cost per dose is $120, with a recommended 3-dose course. The quadrivalent vaccine is the most widely administered worldwide. As with the bivalent and 9-valent vaccines, the vaccine is considered safe, although concerns have been raised. In addition to immunization against the targeted HPV types, there is evidence that there is cross protection against other types of HPV.

Source: Journal of the American Academy of Dermatology - October 16, 2015 Category: Dermatology Authors: Nancy S. Handler, Marc Z. Handler, Slawomir Majewski, Robert A. Schwartz Tags: Continuing medical education Source Type: research